Effects of Amlodipine, Captopril, and Bezafibrate on Oxidative Milieu in Rats with Fatty Liver

  title={Effects of Amlodipine, Captopril, and Bezafibrate on Oxidative Milieu in Rats with Fatty Liver},
  author={Zvi Ackerman and Mor Oron-Herman and Talma Rosenthal and Orit Pappo and Gabriela Link and Ben-ami Sela and Maria Grozovski},
  journal={Digestive Diseases and Sciences},
Oxidative stress may initiate significant hepatocyte injury in subjects with fatty liver. We characterized changes in hepatic oxidative anti-oxidative parameters in rats given a fructose-enriched diet (FED) with and without medications to reduce blood pressure or plasma triglycerides. FED rats had an increase in malondialdehyde (MDA) concentration, a reduction in α-tocopherol concentration, a reduction in paraoxonase (PON) activity, an increase in glutathione peroxidase (GSH-Px), and… 

Effects of Antihypertensive and Triglyceride‐lowering Agents on Hepatic Copper Concentrations in Rats with Fatty Liver Disease

Changes in plasma and hepatic copper concentrations were correlated with changes observed in the immunohistochemical hepatic expression of copper–zinc–superoxide dismutase, metallothionein and nitrotyrosine in rats with the metabolic syndrome and NAFLD as a result of FED with pharmacological manipulations to reduce blood pressure or plasma triglycerides.

Anti-oxidative effect of apocynin on insulin resistance in high-fat diet mice.

The results suggest that apocynin may ameliorate insulin resistance by reducing systemic and hepatic oxidative stress in HFD fed mice.

Hepatic effects of rosiglitazone in rats with the metabolic syndrome.

Administration of rosiglitazone, to rats with the metabolic syndrome has limited hepatic favourable effects: it improves hepatic lipid metabolism, decreases macrovesicular steatosis and improves some of the hepatic oxidative-anti-oxidative milieu but has no effect on hepatic fibrosis.

Effects of Antihypertensive and Triglyceride Lowering Agents on Splenocyte Apoptosis in Rats with Fatty Liver

Changing changes in splenocyte apoptosis in FED rats given medications to treat various components of the metabolic syndrome and non‐alcoholic fatty liver disease were characterized to lead to divergent changes in the splenic histology and splenocytes apoptosis.

Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet.

Overall, nifedipine treatment resulted in an improvement in NASH, similar to bezafibrate, in a rat model, and may provide additional benefits, beyond its blood pressure-lowering effects, to prevent NASH and fatty liver disease.

The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease.


The unlike effects of the two compounds of the same class of L-type calcium channel blockers suggests distinct mechanisms of action and prefigures a new therapeutic strategy for oxidative stress reduction in patients with arterial hypertension.

PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways

The state of knowledge on Pon1 biochemistry and function, the influence of genetic variation, and the regulation of PON1 expression by pharmaceutical compounds that increase PPAR activity are reviewed.

Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice.

The data suggest that the formation of reactive oxygen species in liver is a key factor in the onset of fatty liver and iNOS is involved in mediating the endotoxin/toll-like receptor 4-dependent effects in the development of fructose-induced fatty liver.

Protective Effect of Captopril and Nigella Sativa Oil against Carbon Tetrachloride Induced Nephrotoxicity in Male Rats

Captopril and nigella sativa oil can be used as therapeutic agents in protection against CCl4 induced nephrotoxicity and this effect is attributed to decrease free radicals generation and apoptosis through inhibition of casapse-3 activity in renal tissue.



Amlodipine and glutathione cycle in hypercholesterolaemia

Accelerated glutathione redox cycle activity of erythrocytes from animals supplemented with amlodipine suggests that this drug may reduce oxidative stress by enhancing the glutathion system, however, this drug does not seem to affect the glutATHioneRedox cycle in the aortic tissue.

Glutathione metabolism and antioxidant enzymes in patients affected by nonalcoholic steatohepatitis.

Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis.

The data show a time course and quantitative relationship between PON1 activity and lipid peroxidation in rats with CCl(4)-induced cirrhosis and suggest that this enzyme plays a significant role within the antioxidant systems in liver microsomes.

Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues.

These findings support the previous reports on the enalapril- and captopril-induced enhancement of endogenous antioxidant defenses and include new data on glutathione-dependent defenses, thus furthering current knowledge on the association of ACE inhibition and antioxidants.

Hepatic induction potency of hypolipidaemic drugs in the rat following long-term administration: influence of different dosing regimens.

The induction profiles of these hypolipidaemic drugs, largely different with once-daily dosing, were shown to be similar after adjusting the frequency of dosing with respect to drug half-life.

The ins and outs of mitochondrial dysfunction in NASH.

Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients.

It is concluded that oxidative stress is developed in the liver of NAFLD patients with steatosis and is exacerbated further in patients with Steatohepatitis, which is associated with CYP2E1 induction.

Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis.

Impaired antioxidant defense mechanisms may be an important factor in the pathogenesis of NASH and treatment approaches that affect the antioxidant enzymes may be beneficial in patients with NASH.